Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers September 21, 2017
Pharmacy Choice - News - Generic Drugs - September 21, 2017

Pharmacy News

 Generic Drugs
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

8/22/17 - CSPC Pharmaceutical Announces 2017 Interim Results
CSPC Pharmaceutical Group Limited, a leading pharmaceutical company in China, is pleased to announce its interim results for the six months ended 30 June 2017. During the Period, the Group recorded sales of approximately HK $7,202 million, representing an increase of 17.2% over the same period of last year. Profit attributable to shareholders was
8/22/17 - Drug firms sell off plants [Sport360]
Perrigo, a big generics maker, agreed to sell its active pharmaceutical ingredient facility in Israel to SK Capital, a private equity firm, for $110 million. Last year it acquired Noramco and Tasmanian Alkaloids, sister opioid manufacturers, from Johnson& Johnson. Bristol-Myers Squibb will sell a biologic drug plant in Bothell, Wash., to Seattle Ge
8/22/17 - Researches divided on health claims for turmeric
It gives curries their color and traditionally was used to dye the vibrant golden robes of Buddhist monks. It may be in your spice cabinet right now but should turmeric also be in your medicine cabinet? On the surface, the claims don't seem outlandish: After all, turmeric has been used in India's Ayurvedic medicine as an anti-inflammatory, cough su
8/22/17 - Samsung Bioepis, Takeda agree to develop biosimilar drugs [Arab Finance (Egypt)]
Samsung Bioepis and Takeda Pharmaceutical have signed a strategic collaboration agreement to develop new biopharmaceuticals, Samsung Bioepis said Monday. Takeda Pharmaceutical also showed enthusiasm for the cooperative agreement. The company is collaborating with Merck, a global Pharmaceutical company, also known as MSD in Korea.
8/21/17 - Biosimilar insulin lispro shown not inferior to Humalog in efficacy or safety
By a News Reporter-Staff News Editor at Clinical Trials Week New Rochelle, NY, A study comparing the safety and efficacy of SAR342434, a biosimilar of insulin lispro-Humalog , found it to be comparable to that of the brand name drug in patients also using insulin glargine. Coauthors Satish Garg, University of Colorado Denver, Karin Wernicke-Pan
8/21/17 - EpiPen maker finalizes settlement for government overcharges
TRENTON, N.J.- EpiPen maker Mylan has finalized a $465 million government agreement settling allegations it overbilled Medicaid for its emergency allergy injectors for a decade- charges brought after rival Sanofi filed a whistleblower lawsuit and tipped off the government. On Thursday, the Department of Justice disclosed that its EpiPen case began
8/21/17 - Erelzi (etanercept), by Sandoz, is now available for patients in Canada for the treatment of multiple inflammatory diseases
Erelzi? has been approved for use in Canada in a manner similar to Enbrel , for the treatment of Rheumatoid Arthritis, Ankylosing Spondylitis, and Polyarticular Juvenile Idiopathic Arthritis 1. First biosimilar approved to treat juvenile idiopathic arthritis. Erelzi TM is the second Sandoz biosimilar available in Canada, strengthening Sandoz' l
8/21/17 - Global Biosimilars Market Size and Forecast 2014-2017 & 2025 - Focus on Recombinant Glycosylated Proteins, Recombinant Non-Glycosylated Proteins, and Recombinant Peptides
In addition, the study focuses on a wealth of information on Biosimilars producers and suppliers. Key Topics:- Identify Biosimilars market size for the year 2013-2015 and forecast the same till 2025- Deriving data for Biosimilars, By Region, By Type and By Application- Identify major driving factors, restraints, challenges for the Biosimilars- and
8/21/17 - Global Biosimilars Market Size and Forecast 2014-2025 - Research and Markets
The "Global Biosimilars Market Size and Forecast" report has been added to Research and Markets' offering. The main objective of the study is to estimate the global market size of the Biosimilars in terms of the value, and forecast of the same till 2025.. -Deriving data for Biosimilars, By Region, By Type and By Application.
8/21/17 - IFC Invests in Nobel Ilac To Improve Access To High-Quality Medicine in Turkey
ISTANBUL, 21 August 2017/ PRNewswire Policy/ IFC, a member of the World Bank Group, is providing a $25 million loan to Nobel Ilac, a leading pharmaceutical company in Turkey and the country's only net exporter in the sector, to help meet the growing demand for innovative, affordable, and high-quality medicine in Turkey. Turkey is largely dominate
8/21/17 - Mylan Advances Access in the Fight Against HIV with the Launch of Three Generic Antiretroviral Medicines in Canada
By a News Reporter-Staff News Editor at AIDS Weekly Mylan Pharmaceuticals ULC, a subsidiary of Mylan N.V., a leading global pharmaceutical company, announced the launch in Canada of three generic products indicated in the treatment of HIV for certain patients. Mylan received final approval from Health Canada for this product and for...
8/21/17 - SK Capital Announces Agreement to Acquire Perrigo Company plc's Active Pharmaceutical Ingredients Business
By a News Reporter-Staff News Editor at Pharma Business Week SK Capital, a private investment firm focused on the specialty materials, chemicals and pharmaceuticals sectors, announced that it has signed a definitive agreement to acquire Perrigo API, Perrigo Company plc's active pharmaceutical ingredients business. SK Capital has effectively execu
8/21/17 - Teva Announces Exclusive Launch of Generic Axiron in the United States
Release date- 18082017- JERUSALEM- Teva Pharmaceutical Industries Ltd., today announced the launch of generic Axiron1 topical solution CIII, 30 mg/1. 5 mL, in the U.S.. With nearly 600 generic medicines available, Teva has the largest portfolio of FDA- approved generic products on the market and holds the leading position in first-to-file opportuni
8/21/17 - Upsher-Smith Launches Newly Designed Website For Qudexy XR (topiramate) Extended-Release Capsules
Upsher-Smith Laboratories, LLC today announced the launch of its enhanced website for Qudexy XR Extended-Release Capsules. The site features Upsher-Smith's Access Pathways? Program designed to reduce the barriers associated with prescribing Qudexy XR. QudexyXR.com offers healthcare professionals the tools necessary to help their patients.
8/21/17 - WHAT THE OTHER PAPERS SAY THIS MORNING
FINANCIAL TIMES LAW GIANT QUITS ADVISING BARCLAYS OVER QATAR LOAN Law firm Linklaters resigned from advising Barclays over a controversial loan to Qatar at the heart of a $1 bn lawsuit over fears it would be illegal, court documents have claimed. HIKMA HIKES PRICE OF US MEDICINES BY UP TO 430 PC Hikma, the London- listed generic drugmaker, has shar
8/20/17 - BRIEF: Teva launches generic testosterone boost treatment [Globes, Tel Aviv, Israel]
Aug. 20 Teva Pharmaceutical Industries Ltd. has announced the launch of generic Axiron topical solution CIII, 30 mg/1. 5 mL, in the US. With nearly 600 generic medicines available, Teva has the largest portfolio of FDA- approved generic products on the market and holds the leading position in first-to-file opportunities, with over 100 pending fir
8/20/17 - Mylan finalizes settlement over Medicaid payments for EpiPen
PITTSBURGH Generic drug giant Mylan announced Thursday it has finalized its settlement with the U.S. Department of Justice for overcharging Medicaid for the EpiPen. The settlement amount is $465 million, unchanged from when Mylan announced a preliminary deal in October that was criticized by lawmakers and others as not being harsh enough.
8/19/17 - Government seeks caps on drug trade margins [Tehran Times (Iran)]
The government plans to cap trade margins to make drugs cheaper, replace brand names with salt names for generic drugs, clamp down on unfair marketing practices and boost local manufacturing to reduce dependence on imports, according to government`s draft national pharmaceutical policy. The draft, prepared by the pharmaceuticals department, also su
8/19/17 - Gwq Generic Tender (tacrolimus-aliud). [TendersInfo (India)]
Contract notice: Gwq generic tender. Conclusion of a generic agreement regarding products with the active ingredient tacrolimus of the manufacturer ALIUD PHARMA GmbH. Time-limit for receipt of tenders or requests to participate: Date 15/08/2017 Local time 1000 IV.2.3) Estimated date of dispatch of invitations to tender or to participate to selected
8/19/17 - Gwq Generic Tender (tacrolimus-astellas). [TendersInfo (India)]
Contract notice: Gwq generic tender. Conclusion of a generic agreement regarding products with the active ingredient Tacrolimus from the manufacturer Astellas Pharma GmbH. Time limit for receipt of tenders or requests to participate: Date: 15/08/2017 Local time: 10:00 Major organization: GWQ SERVICEPLUS AG Address: Tersteegenstr. 28 Dsseldorf 40476
8/19/17 - Gwq Generic Tender (tacrolimus-heumann). [TendersInfo (India)]
Contract notice: Gwq generic tender. Conclusion of a generic agreement agreement for products with the active ingredient Tacrolimus from the manufacturer Heumann Pharma GmbH& Co. Generika KG. Time limit for receipt of tenders or requests to participate: Date: 15/08/2017 Local time: 10:00 Major organization: GWQ SERVICEPLUS AG Address: Tersteegenstr
8/19/17 - Gwq Generic Tender (tacrolimus-stada). [TendersInfo (India)]
Contract notice: Gwq generic tender. Conclusion of a generic agreement agreement for products with the active substance tacrolimus of the manufacturer STADApharm GmbH. Time limit for receipt of tenders or requests to participate: Date: 15/08/2017 Local time: 10:00 Major organization: GWQ SERVICEPLUS AG Address: Tersteegenstr. 28 Dsseldorf 40474 Ger
8/18/17 - Biocons biosimilars withdrawn in EU [Algeria Press Service]
Corrective and preventive actions will be completed by the end of this quarter and Biocon hopes to ask for a re-inspection once they are complete, followed by a refiling. Biocon and partner Mylan became the first companies to file a biosimilar of Roches big-selling breast cancer drug Herceptin in the EU last summer, shortly after filing a biosimila
8/18/17 - Clinical Trial Supplies Market is Anticipate To Accelerate Growth Owing To Increasing Complexities, Rising Number Of Biologics And Biosimilar Drugs Till 2025: Grand View Research, Inc.
"Grand View Research, Inc.- Market Research And Consulting." According to report published by Grand View Research, Global Clinical Trial Supplies Market size was valued at USD 1.7 billion in 2016 and Advancement in supply chain management technology is also expected to be the major driver for growth of the supplies market. The Global Clinical Trial
8/18/17 - Company Spotlight: ANI Pharmaceuticals
WASHINGTON- In today's Spotlight column, the company we are featuring is ANI Pharmaceuticals Inc.. ANI Pharma develops, manufactures and markets branded and generic prescription pharmaceuticals, and also provides contract manufacturing services to select clients. ANI Pharmaceuticals also has a well-stocked pipeline- with 71 generic products and 5..
Articles(s): 1 - 25 of 250     Next >>     Go To Page:


© 2017 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Legal & Practical Issues in Compounding Pharmacy
This lesson is supported by:
RxSchool
Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
RxSchool
Pharmacy Spanish
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415